To include your compound in the COVID-19 Resource Center, submit it here.
AbbVie began double-blind, placebo-controlled, U.S. Phase III trial to evaluate oral elagolix with
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury